Literature DB >> 7575434

Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family.

I McPhee1, L Pooley, M Lobban, G Bolger, M D Houslay.   

Abstract

COS-7 cells were transfected with a plasmid encoding a putative splice variant of PDE4A cyclic AMP-specific phosphodiesterase, RPDE-6 (RNPDE4A5). This led to the expression of a novel, cyclic AMP-specific, rolipram-inhibited phosphodiesterase activity. In such transfected cells a novel approximately 109 kDa species was recognized by anti-peptide sera raised against a dodecapeptide whose sequence is found at the extreme C-terminus of both RPDE-6 and another PDE4A splice variant. RD1 (RNPDE4A1A). RPDE-6 activity and immunoreactivity was found distributed between both pellet (approximately 25%) and cytosol (approximately 75%) fractions of transfected COS-7 cells. Soluble and pellet RPDE-6 activities exhibited similar low Km values for cyclic AMP (approximately 2.4 microM) and were both inhibited by low concentrations of rolipram, with IC50 values for the soluble activity being lower (approximately 0.16 microM) than for the pellet activity (approximately 1.2 microM). Pellet RPDE-6 was resistant to release by either high NaCl concentrations or the detergent Triton X-100. Probing brain homogenates with the anti-(C-terminal peptide) sera identified two immunoreactive species, namely an approximately 79 kDa species reflecting RD1 and an approximately 109 kDa species that co-migrated with the immunoreactive species seen in COS cells transfected to express RPDE-6. The approximately 109 kDa species was found distributed between both the low-speed (P1) and high-speed (P2) pellet fractions as well as the cytosol fractions derived from both brain and RPDE-6-transfected COS cells. In contrast, RD1 was found exclusively in the P2 fraction. Phosphodiesterase (PDE) activity immuno-precipitated by these antisera from brain cytosol had the characteristics of COS cell-expressed RPDE-6 with KmcyclicAMP approximately 3.7 microM and IC50rolipram approximately 0.12 microM. The distribution of PDE activity immunoprecipitated from the cytosol of various brain regions paralleled that seen for the distribution of the approximately 109 kDa immunoreactive species. It is suggested that the 109 kDa species identified in brain cytosol and pellet fractions is the native form of RPDE-6. The PDE4A splice variants, RD1 and RPDE-6, were shown to have distinct patterns of expression among various brain regions. PDE4A and PDE4B activities appear to provide the major source of PDE4 activity in brain membranes, whereas the cytosolic PDE4 activity is suggested to reflect predominantly the activity of the PDE4D family. Alternative splicing of the PDE4A gene confers distinct N-terminal domains on RPDE-6 and RD1, which attenuates the Vmax. of these enzymes and defines their distinct subcellular distribution pattern.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575434      PMCID: PMC1135990          DOI: 10.1042/bj3100965

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  31 in total

1.  Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram.

Authors:  Y Shakur; J G Pryde; M D Houslay
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

2.  Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases. Multiple mRNA variants originate from alternative splicing and multiple start sites.

Authors:  L Monaco; E Vicini; M Conti
Journal:  J Biol Chem       Date:  1994-01-07       Impact factor: 5.157

3.  Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phosphodiesterase (PDE IVD).

Authors:  P A Baecker; R Obernolte; C Bach; C Yee; E R Shelton
Journal:  Gene       Date:  1994-01-28       Impact factor: 3.688

4.  The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase.

Authors:  C Sette; E Vicini; M Conti
Journal:  J Biol Chem       Date:  1994-07-15       Impact factor: 5.157

5.  A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA.

Authors:  M M McLaughlin; L B Cieslinski; M Burman; T J Torphy; G P Livi
Journal:  J Biol Chem       Date:  1993-03-25       Impact factor: 5.157

6.  A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs.

Authors:  G Bolger; T Michaeli; T Martins; T St John; B Steiner; L Rodgers; M Riggs; M Wigler; K Ferguson
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

7.  Chromosome localizations of genes for five cAMP-specific phosphodiesterases in man and mouse.

Authors:  A Milatovich; G Bolger; T Michaeli; U Francke
Journal:  Somat Cell Mol Genet       Date:  1994-03

8.  Adhesion receptor activation of phosphatidylinositol 3-kinase. von Willebrand factor stimulates the cytoskeletal association and activation of phosphatidylinositol 3-kinase and pp60c-src in human platelets.

Authors:  S P Jackson; S M Schoenwaelder; Y Yuan; I Rabinowitz; H H Salem; C A Mitchell
Journal:  J Biol Chem       Date:  1994-10-28       Impact factor: 5.157

9.  Isolation of a matrix that binds medial Golgi enzymes.

Authors:  P Slusarewicz; T Nilsson; N Hui; R Watson; G Warren
Journal:  J Cell Biol       Date:  1994-02       Impact factor: 10.539

10.  Site-specific mutations in the COOH-terminus of placental alkaline phosphatase: a single amino acid change converts a phosphatidylinositol-glycan-anchored protein to a secreted protein.

Authors:  M E Lowe
Journal:  J Cell Biol       Date:  1992-02       Impact factor: 10.539

View more
  27 in total

1.  Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.

Authors:  Patricia Goldhoff; Nicole M Warrington; David D Limbrick; Andrew Hope; B Mark Woerner; Erin Jackson; Arie Perry; David Piwnica-Worms; Joshua B Rubin
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 2.  PDE4 as a target for cognition enhancement.

Authors:  Wito Richter; Frank S Menniti; Han-Ting Zhang; Marco Conti
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

3.  Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes.

Authors:  S J MacKenzie; S J Yarwood; A H Peden; G B Bolger; R G Vernon; M D Houslay
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

4.  The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5).

Authors:  J C O'Connell; J F McCallum; I McPhee; J Wakefield; E S Houslay; W Wishart; G Bolger; M Frame; M D Houslay
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

5.  Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior.

Authors:  Rolf T Hansen; Marco Conti; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

6.  Co-transfection with protein kinase D confers phorbol-ester-mediated inhibition on glucagon-stimulated cAMP accumulation in COS cells transfected to overexpress glucagon receptors.

Authors:  E S Tobias; E Rozengurt; J M Connell; M D Houslay
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

Review 7.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

8.  Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

Authors:  E Huston; S Lumb; A Russell; C Catterall; A H Ross; M R Steele; G B Bolger; M J Perry; R J Owens; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

Review 9.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.

Authors:  M Takahashi; R Terwilliger; C Lane; P S Mezes; M Conti; R S Duman
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.